In term PE, a good clinical strategy based on the currently available knowledge could be to rule out PE using the high NPV of the sFlt-1:PlGF ratio ≤ 38 in women who are clinically suspicious for PE but for whom uncertainty regarding the diagnosis still exists (e.g., symptoms of PE without clinical signs or proteinuria without hypertension). This evidence concerns the gene PGF and Hypertension.